Covered recipient · General Payments record
JOHN S HROM
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,710.38
77 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,710.38 | 77 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $243.60 | 6 |
| PFIZER INC. | $182.21 | 11 |
| Exelixis Inc. | $160.19 | 5 |
| Novartis Pharmaceuticals Corporation | $118.64 | 6 |
| E.R. Squibb & Sons, L.L.C. | $115.68 | 7 |
| Celgene Corporation | $114.33 | 5 |
| Gilead Sciences, Inc. | $103.79 | 4 |
| GENZYME CORPORATION | $82.73 | 4 |
| Spectrum Pharmaceuticals Inc. | $68.74 | 2 |
| Octapharma USA, Inc. | $67.27 | 3 |
| AstraZeneca Pharmaceuticals LP | $65.47 | 4 |
| Janssen Biotech, Inc. | $53.09 | 3 |
| JAZZ PHARMACEUTICALS INC. | $50.00 | 2 |
| SpringWorks Therapeutics, Inc. | $48.61 | 3 |
| Daiichi Sankyo Inc. | $43.21 | 2 |
| Astellas Pharma US Inc | $35.88 | 2 |
| Deciphera Pharmaceuticals Inc. | $24.30 | 1 |
| Merck Sharp & Dohme LLC | $22.75 | 1 |
| GlaxoSmithKline, LLC. | $21.87 | 1 |
| TAIHO ONCOLOGY, INC. | $21.46 | 1 |
| Genentech USA, Inc. | $17.77 | 1 |
| ADC Therapeutics America, Inc. | $17.64 | 1 |
| Myriad Genetic Laboratories, Inc. | $15.67 | 1 |
| Mirati Therapeutics, Inc. | $15.48 | 1 |
Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN S HROM
NPI 1134238496 · CMS profile ID 232451
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
HATTIESBURG, MS
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1134238496?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN S HROM, NPI 1134238496, CMS profile ID 232451. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134238496?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JOHN S HROM, NPI 1134238496, CMS profile ID 232451. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134238496?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JOHN S HROM, NPI 1134238496, CMS profile ID 232451, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1134238496?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
77 matching records · $1,710.38 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–77 of 77.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $21.17 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139758238 | CMS |
| Novartis Pharmaceuticals Corporation | $18.42 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086872809 | CMS |
| Mirati Therapeutics, Inc. | $15.48 | 03/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117163497 | CMS |
| Celgene Corporation | $25.05 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101100929 | CMS |
| Novartis Pharmaceuticals Corporation | $16.66 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086872813 | CMS |
| Genentech USA, Inc. | $17.77 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133035069 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.01 | 03/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104232581 | CMS |
| Myriad Genetic Laboratories, Inc. | $15.67 | 03/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152532854 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.22 | 03/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101291942 | CMS |
| Merck Sharp & Dohme LLC | $22.75 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141577751 | CMS |
| Spectrum Pharmaceuticals Inc. | $49.10 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150655619 | CMS |
| Celgene Corporation | $24.76 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101100927 | CMS |
| Octapharma USA, Inc. | $20.35 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142315480 | CMS |
| Astellas Pharma US Inc | $19.81 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139318584 | CMS |
| TAIHO ONCOLOGY, INC. | $21.46 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137934557 | CMS |
| Exelixis Inc. | $13.99 | 02/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138559572 | CMS |
| Gilead Sciences, Inc. | $24.22 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133798882 | CMS |
| ABBVIE INC. | $60.83 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103945365 | CMS |
| PFIZER INC. | $13.89 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131285067 | CMS |
| Janssen Biotech, Inc. | $17.24 | 02/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078805395 | CMS |
| Novartis Pharmaceuticals Corporation | $19.18 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086872807 | CMS |
| PFIZER INC. | $20.55 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131285063 | CMS |
| Octapharma USA, Inc. | $22.20 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142315478 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.88 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101291936 | CMS |
| GENZYME CORPORATION | $21.74 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139758184 | CMS |
| PFIZER INC. | $22.04 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131202420 | CMS |
| SpringWorks Therapeutics, Inc. | $15.53 | 01/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1085805195 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $73.00 | 2 |
| PY2025 | Principal investigator | $1,437,415.12 | 176 |
| PY2024 | Recipient | $768.71 | 2 |
| PY2024 | Principal investigator | $1,138,869.99 | 139 |
| PY2023 | Recipient | $111.00 | 4 |
| PY2023 | Principal investigator | $965,036.70 | 82 |
| PY2022 | Principal investigator | $865,848.90 | 73 |
| PY2021 | Principal investigator | $1,897,381.57 | 88 |
| PY2020 | Principal investigator | $1,471,650.77 | 234 |
| PY2019 | Principal investigator | $2,249,708.72 | 74 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
178 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $216.00 | 12/31/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting | No dispute reported | 06/30/2026 | 1202532386 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $187,257.16 | 12/31/2025 | Non-covered Recipient Entity Hattiesburg Clinic Hematology,Oncology | A Randomized, Open label, Phase 3 Study of MK-2870 in Combination with Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer with PD-L1 TPS Greater Than or Equal To 50 | No dispute reported | 06/30/2026 | 1232923232 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $9,161.59 | 12/31/2025 | Non-covered Recipient Entity Hattiesburg Clinic Hematology,Oncology | A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy Docetaxel or Pemetrexed in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC with EGFR Mutations or Other Genomic Alterations | No dispute reported | 06/30/2026 | 1232923486 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $19,620.02 | 12/31/2025 | Non-covered Recipient Entity Hattiesburg Clinic Hematology,Oncology | A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatm | No dispute reported | 06/30/2026 | 1232928672 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,433.80 | 12/31/2025 | Non-covered Recipient Entity Hattiesburg Clinic | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies | No dispute reported | 06/30/2026 | 1232931250 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $624.00 | 12/30/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190337428 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $11,500.00 | 12/29/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC HEMATOLOGY AND ONCOLOGY | A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) | No dispute reported | 06/30/2026 | 1185548343 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 12/19/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184278054 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,664.00 | 12/18/2025 | Non-covered Recipient Entity Hattiesburg Clinic Family Practice | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1235997015 |
| Principal investigator 1 | ABBVIE INC. | $5,116.80 | 12/04/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202527194 |
| Principal investigator 1 | ABBVIE INC. | $2,401.75 | 12/04/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202527196 |
| Principal investigator 1 | Incyte Corporation | $1,402.96 | 12/04/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC HEM | INCB50465-801, Ph2, Roll-Over Study | No dispute reported | 06/30/2026 | 1240538030 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $13,391.00 | 12/03/2025 | Non-covered Recipient Entity Hattiesburg Clinic - Hattiesburg | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1235997017 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,351.00 | 12/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398602 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,099.00 | 11/28/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175398678 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,137.85 | 11/27/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184265595 |
| Principal investigator 1 | ABBVIE INC. | $4,102.80 | 11/20/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202524782 |
| Principal investigator 1 | ABBVIE INC. | $3,000.01 | 11/20/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202525050 |
| Principal investigator 1 | BeOne Medicines Ltd. | $52,400.00 | 11/17/2025 | Non-covered Recipient Entity Forrest General Hospital Cancer Center | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190337172 |
| Principal investigator 1 | ABBVIE INC. | $2,393.30 | 11/05/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202521725 |
| Principal investigator 1 | ABBVIE INC. | $14,379.30 | 11/05/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202521727 |
| Principal investigator 1 | PFIZER INC. | $3,900.00 | 11/04/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228730500 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,368.00 | 11/03/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398622 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 10/29/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184254343 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $624.00 | 10/28/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190337425 |
| Principal investigator 1 | Janssen Research & Development, LLC | $285.00 | 10/24/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398616 |
| Principal investigator 1 | Incyte Corporation | $1,188.72 | 10/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC HEM | INCB50465-801, Ph2, Roll-Over Study | No dispute reported | 06/30/2026 | 1240538023 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 10/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC HEM | INCB50465-801, Ph2, Roll-Over Study | No dispute reported | 06/30/2026 | 1240538027 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,060.00 | 10/22/2025 | Non-covered Recipient Entity Hattiesburg Clinic | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies | No dispute reported | 06/30/2026 | 1232931248 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,224.00 | 10/13/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398656 |
| Principal investigator 1 | ABBVIE INC. | $4,967.30 | 10/09/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202514193 |
| Principal investigator 1 | ABBVIE INC. | $9,965.80 | 10/09/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202514195 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,512.00 | 10/08/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies | No dispute reported | 06/30/2026 | 1190329271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.35 | 10/03/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184245381 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 10/03/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184245383 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,248.00 | 09/23/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190337419 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,429.00 | 09/22/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175398725 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,445.00 | 09/19/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398661 |
| Principal investigator 1 | ABBVIE INC. | $9,916.40 | 09/04/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202509332 |
| Principal investigator 1 | ABBVIE INC. | $2,393.30 | 09/04/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202509802 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,964.00 | 09/02/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190337414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 09/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184233282 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.35 | 09/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184233284 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,106.50 | 09/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184233286 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 09/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184233288 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.35 | 09/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184233290 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 09/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184233292 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,668.55 | 09/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184233294 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $108.30 | 09/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184233296 |
| Principal investigator 1 | BeOne Medicines Ltd. | $52,400.00 | 08/25/2025 | Non-covered Recipient Entity Forrest General Hospital Cancer Center | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190344188 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,914.00 | 08/25/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398740 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,389.00 | 08/11/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398565 |
| Principal investigator 1 | ABBVIE INC. | $10,078.90 | 08/06/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202502492 |
| Principal investigator 1 | ABBVIE INC. | $3,152.50 | 08/06/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202502494 |
| Principal investigator 1 | BeOne Medicines Ltd. | $52,400.00 | 08/05/2025 | Non-covered Recipient Entity Forrest General Hospital Cancer Center | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190330205 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,548.00 | 08/04/2025 | Non-covered Recipient Entity Hattiesburg Clinic, Pa | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226089832 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,000.00 | 08/01/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190327123 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,000.00 | 08/01/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190327297 |
| Principal investigator 1 | BeOne Medicines Ltd. | $609.00 | 08/01/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190327305 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,895.00 | 07/24/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398733 |
| Principal investigator 1 | ABBVIE INC. | $9,639.65 | 07/10/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202497952 |
| Principal investigator 1 | ABBVIE INC. | $9,916.40 | 07/08/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202497298 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,350.00 | 07/07/2025 | Non-covered Recipient Entity Hattiesburg Clinic, Pa | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226089826 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,457.00 | 07/04/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398642 |
| Principal investigator 1 | Celgene Corporation | $22,455.00 | 06/27/2025 | Non-covered Recipient Entity Hattiesburg Clinic, Pa | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1222305262 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,674.00 | 06/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398650 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,512.00 | 06/20/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190326216 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $777.00 | 06/17/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190326080 |
| Principal investigator 1 | ABBVIE INC. | $8,606.40 | 06/12/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202491365 |
| Principal investigator 1 | BeOne Medicines Ltd. | $52,400.00 | 06/09/2025 | Non-covered Recipient Entity Forrest General Hospital Cancer Center | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190330273 |
| Principal investigator 1 | ABBVIE INC. | $10,078.90 | 06/03/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202489787 |
| Recipient | ABBVIE INC. | $48.00 | 05/30/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202398921 |
| Recipient | ABBVIE INC. | $25.00 | 05/30/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202398925 |
| Principal investigator 1 | ABBVIE INC. | $8,305.80 | 05/28/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202486457 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,057.86 | 05/27/2025 | Non-covered Recipient Entity Hattiesburg Clinic Hematology Oncology | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1235997011 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,337.00 | 05/26/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398715 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $323.70 | 05/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184198433 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $596.70 | 05/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184198435 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $419.90 | 05/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184198437 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,616.90 | 05/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184198439 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,876.90 | 05/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184198441 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $533.00 | 05/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184198443 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $15,688.00 | 05/12/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190331411 |
| Principal investigator 1 | ABBVIE INC. | $4,706.00 | 05/07/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202482813 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,700.00 | 05/05/2025 | Non-covered Recipient Entity Hattiesburg Clinic, Pa | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226089821 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,616.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191683 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,876.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191685 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,876.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191687 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,876.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191689 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,876.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191691 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,616.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191693 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,876.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191695 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,616.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191697 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,876.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191699 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,876.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191701 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,423.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191703 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,423.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191705 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,616.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191707 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,616.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191709 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $596.70 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191711 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,616.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191713 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,574.00 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191715 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,005.30 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191717 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,876.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191719 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,616.90 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184191721 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.35 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190861 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.35 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190863 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190865 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.35 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190867 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,425.70 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190869 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.35 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190871 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190873 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,566.30 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190875 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $108.30 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190877 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190879 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190881 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.35 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190883 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,649.90 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190885 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,104.60 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190887 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,649.90 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190889 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,329.75 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190891 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,424.75 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190893 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,329.75 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190895 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190897 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.35 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190899 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $108.30 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190901 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,425.70 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190903 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,649.90 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.35 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190909 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,201.50 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,175.60 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190913 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.35 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,566.30 | 04/30/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184190917 |
| Principal investigator 1 | Celgene Corporation | $46,588.50 | 04/25/2025 | Non-covered Recipient Entity Hattiesburg Clinic Hematology And Oncology | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1222304491 |
| Principal investigator 1 | ABBVIE INC. | $7,229.70 | 04/24/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202479111 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $58,319.00 | 04/24/2025 | Non-covered Recipient Entity Hattiesburg Clinic Hematology Oncology | A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers | No dispute reported | 06/30/2026 | 1235997009 |
| Principal investigator 1 | Incyte Corporation | $2,971.80 | 04/24/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC HEM | INCB50465-801, Ph2, Roll-Over Study | No dispute reported | 06/30/2026 | 1240538018 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,768.00 | 04/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184186231 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,900.00 | 04/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184186233 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,302.40 | 04/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184186235 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,702.00 | 04/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS | No dispute reported | 06/30/2026 | 1184186237 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,900.00 | 04/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184186239 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,702.00 | 04/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184186241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,302.40 | 04/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184186243 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,768.00 | 04/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184186245 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,986.00 | 04/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184189017 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,525.00 | 04/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184189019 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,558.00 | 04/21/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398591 |
| Principal investigator 1 | ABBVIE INC. | $4,163.90 | 04/17/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202477250 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,248.00 | 04/17/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190326082 |
| Principal investigator 1 | Celgene Corporation | $8,976.50 | 04/17/2025 | Non-covered Recipient Entity Hattiesburg Clinic Hematology And Oncology | A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) | No dispute reported | 06/30/2026 | 1222304561 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $39,628.00 | 04/16/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190338170 |
| Principal investigator 1 | BeiGene, Ltd. | $33,536.00 | 04/16/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190322296 |
| Principal investigator 1 | ABBVIE INC. | $12,000.10 | 04/03/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202471558 |
| Principal investigator 1 | ABBVIE INC. | $10,078.90 | 04/03/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202471561 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,519.00 | 04/02/2025 | Non-covered Recipient Entity Hattiesburg Clinic, Pa | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226089808 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,779.00 | 03/24/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398706 |
| Principal investigator 1 | ABBVIE INC. | $10,445.90 | 03/20/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | M24-977 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202465049 |
| Principal investigator 1 | ABBVIE INC. | $10,291.15 | 03/20/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202465078 |
| Principal investigator 1 | Celgene Corporation | $1,910.00 | 03/19/2025 | Non-covered Recipient Entity Advarra | A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) | No dispute reported | 06/30/2026 | 1222307115 |
| Principal investigator 1 | BeiGene, Ltd. | $52,400.00 | 03/17/2025 | Non-covered Recipient Entity Forrest General Hospital Cancer Center | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190323682 |
| Principal investigator 1 | BeiGene, Ltd. | $1,512.00 | 03/14/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190320076 |
| Principal investigator 1 | ABBVIE INC. | $12,862.85 | 03/12/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202462673 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,968.00 | 03/10/2025 | Non-covered Recipient Entity Hattiesburg Clinic, Pa | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226089814 |
| Principal investigator 1 | ABBVIE INC. | $26,800.80 | 03/07/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202460136 |
| Principal investigator 1 | ABBVIE INC. | $17,020.90 | 03/07/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | M24-977 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) | No dispute reported | 06/30/2026 | 1202460278 |
| Principal investigator 1 | BioNTech SE | $8,000.00 | 03/04/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | BNT327-01 | No dispute reported | 06/30/2026 | 1249011548 |
| Principal investigator 1 | Celgene Corporation | $12,378.00 | 02/21/2025 | Non-covered Recipient Entity Hattiesburg Clinic, Pa | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1222305306 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,779.00 | 02/20/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398586 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,867.00 | 02/18/2025 | Non-covered Recipient Entity Hattiesburg Clinic, Pa | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226089794 |
| Principal investigator 1 | BeiGene, Ltd. | $1,512.00 | 02/14/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190320000 |
| Principal investigator 1 | ABBVIE INC. | $2,835.30 | 02/06/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202447175 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,201.16 | 01/27/2025 | Non-covered Recipient Entity Hattiesburg Clinic Hematology Oncology | A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) | No dispute reported | 06/30/2026 | 1235997005 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,971.74 | 01/27/2025 | Non-covered Recipient Entity Hattiesburg Clinic Hematology Oncology | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1235997007 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,476.00 | 01/27/2025 | Non-covered Recipient Entity Hattiesburg Clinic, Pa | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226089800 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,779.00 | 01/20/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1175398709 |
| Principal investigator 1 | BeiGene, Ltd. | $325.00 | 01/15/2025 | Non-covered Recipient Entity Hattiesburg Hematology and Oncology Clinic | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190320004 |